References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailIncidence of osteoporotic non vertebral fractures coming in the strontium ranelate run-in study could validate sample size calculation
Reginster, Jean-Yves ULg; Meunier, Pierre J

in Osteoporosis International (2002, November), 13(Suppl.3), 36

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailComparison of quantitative ultrasound at the heel with a clinical risk factor score for the assessment of postmenopausal osteoporosis
Goemare, S.; Zmierczak, H.; Lauwerier, D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 36

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailA simple chart for evaluating risk of osteoporosis in Asian women based on the osteoporosis self-assement tool for Asians (OSTA)
Reginster, Jean-Yves ULg; Kung, A.; Koh, L. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 30

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailComparison of the osteorisk, an osteoporosis risk assessment tool in latin america, with the osteoporosis self-assessment tool (OST)
Sen, S. S.; Geling, O.; Messina, O. D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 27-28

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailComparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis
Kung, A. W. C.; Ho, A. Y. Y.; Ben Sedrine, W. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 30-31

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: new efficient anti-osteoporotic agent for treatment of vertebral osteoporosis in postmenopausal women
Meunier, Pierre J; Lorenc, R. S.; Smith, I. G. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 34

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailIdentification of key predictors for osteoporosis through use of different analytical techniques
Sen, S. S.; Geling, O.; Messina, O. D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 27

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailComparison of body weight and body mass index as predictors for osteoporosis among postmenopausal latin american women
Sen, S. S.; Geling, O.; Messina, O. D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 27

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailSupplementation of calcium-vitamin D should be adapted according to the patients status in international phase 3 program on osteoporosis
Reginster, Jean-Yves ULg; Diez-Perez, A.; Ortolani, S. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 35

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailA risk assessment tool (OSTEORISK) for identifying latin american women with osteoporosis
Sen, S. S.; Geling, O.; Messina, O. D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 26-27

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailEfficacy of D-Hormones in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate
Richy, Florent; Reginster, Jean-Yves ULg

in Osteoporosis International (2002, November), 13(Suppl.3), 21

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailType II collagen derived fragment (COLL2-1) is new marker predictive of osteoarthritis progression
Henrotin, Yves ULg; Deberg, M.; Christgau, S. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 17

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailOnce-weekly alendronate produces a greater decrease in bone resorption than daily risedronate
Adami, Silvio; Felsenberg, D.; Hosking, D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 14-15

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailTraitement hormonal de la menopause: traitement hormonal substitutif classique ou tibolone?
Reginster, Jean-Yves ULg

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (2002), 31(6), 541-9

OBJECTIVE: Our purpose was to review with critical analysis, data from randomized controlled clinical trials comparing the effects on bone of conventional hormone replacement therapy (HRT) and tibolone ... [more ▼]

OBJECTIVE: Our purpose was to review with critical analysis, data from randomized controlled clinical trials comparing the effects on bone of conventional hormone replacement therapy (HRT) and tibolone. Their respective effects on bone were also reviewed and summarized. Materials and methods. Medline via PubMed was searched using a combination of the following key words "tibolone, estrogens and bone" to identify all randomized controlled trials tibolone versus HRT (1960-2001). RESULTS: Six randomized controlled trials that have been carried out to compare effects of tibolone and conventional HRT on prevention of postmenopausal bone loss were identified. Only one of these trials has been performed with a correct methodology (double-blind and with an adequate duration). In this trial over 2 years, the highest significant increase from baseline in bone mineral density (BMD) at all sites was observed with HRT; in addition, HRT showed a significantly greater increase in BMD at lumbar spine than tibolone. Randomized placebo-controlled trials have demonstrated that tibolone produces positive effects on BMD. Nevertheless, no clinical convincing data are available to support its efficacy in the prevention of osteoporotic fractures. The positive impact on BMD of conventional HRT to prevent postmenopausal bone loss and to treat established osteoporosis has been shown by many randomized controlled trials. Regarding fracture risk prevention, some clinical and epidemiological data suggest that HRT initiated in early or late postmenopause may prevent fractures if it is administered at standard doses and continued for a long time. CONCLUSION: HRT is always the reference treatment of postmenopausal symptoms related to estrogen deficiency. [less ▲]

Detailed reference viewed: 123 (0 ULg)
Full Text
Peer Reviewed
See detailOnce weekly alendronate produces a greater decrease in bone resorption than does daily risedronate
Hosking, D.; Adami, S.; Felsenberg, D. et al

in Journal of Bone and Mineral Research (2002, September), 17(S1), 370

Detailed reference viewed: 11 (8 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Sawicki, A.; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 584-5

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailDevelopment of new immunoassays for the quantification of inflammatory related cartilage degradation
Deberg, Michelle ULg; Christgau, Stephan; Henriksen, Dennis et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 496

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailLumiracoxib (Prexige) is effective in the treatment of osteoarthritis of the knee: a 13-week, placebo-controlled, active-comparator, double-blind study
Tannenbaum, Hyman; Berenbaum, Francis; Reginster, Jean-Yves ULg et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 212

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailDo willingness to pay and time trade-off approaches suitably reflect health outcomes in hip and knee osteoarthritis?
Ethgen, Olivier ULg; Tancredi, Annalisa; Lejeune, Eric ULg et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 73

Detailed reference viewed: 8 (4 ULg)